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Binding of extracellular ligands to epidermal growth
factor receptors (EGFR) activate signal transduction
pathways associated with cell proliferation, and these
events are inhibited by monoclonal antibodies against
EGFR. Since efficient DNA repair in actively growing
cells may require growth factor signaling, it was of inter-
est to explore any linkage between EGFR-mediated sig-
naling and DNA-dependent protein kinase (DNA-PK), an
enzyme believed to be involved in repairing double
strand breaks and V(D)J recombination. We report that
anti-EGFR monoclonal antibodies (mAbs), and not EGFR
ligands, trigger a specific early physical interaction be-
tween EGFR and a 350-kDa catalytic subunit of DNA or its
regulatory heterodimeric complex Ku70/80, in a variety of
cell types, both in vivo and in vitro. Inhibition of EGFR
signaling by anti-EGFR mAb was accompanied by a re-
duction in the levels of the DNA-PK and its activity in the
nuclear fraction. Confocal imaging revealed that a sub-
stantial amount of DNA-PK was co-localized with EGFR
in anti-EGFR mAb-treated cells. Anti-EGFR mAb-induced
physical interaction between EGFR and DNA-PK or
Ku70/80 was dependent on the presence of EGFR, but not
on the levels of EGFR. The EGFR associated with DNA-PK
or Ku70/80 retains its intrinsic kinase activity. Our find-
ings demonstrate the existence of a novel cellular path-
way in mammalian cells that involves physical interac-
tions between EGFR and DNA-PK or Ku70/80 in response
to inhibition of EGFR signaling. Our present observations
suggest a possible role of EGFR signaling in maintenance
of the nuclear levels of DNA-PK, and interference in
EGFR signaling may possibly result in the impairment of
DNA repair activity in the nuclei in anti-EGFR mAb-
treated cells.
The mitogenic effects of growth stimulatory polypeptides are
regulated by their binding to high affinity transmembrane
receptors with intrinsic kinase activity (1–3). The epidermal
growth factor is one of the well characterized growth factor that
stimulates the proliferation of fibroblasts and most types of
epithelial cells (4). Modifications of EGFR1 induced by extra-
cellular ligands such as EGF or TGF-a lead to engagement of
EGFR with signal transduction pathways associated with mi-
togenesis and cell proliferation (1–5). Overexpression of EGFR,
as well as its natural ligand TGF-a, has been shown to induce
transformed properties in recipient cells (6). In recent years,
approaches involving interference with and/or blocking of
EGFR-mediated growth stimulation by anti-EGFR monoclonal
antibodies have been the subject of active investigation in an
effort to control cell proliferation (7). mAbs 528 and 225, raised
against the extracellular domain of EGFR, have been shown to
bind to the receptors with high affinity comparable with the
natural ligand, compete for binding of TGF-a or EGF, and block
both ligand-induced activation of EGFR kinase activity and
growth stimulation of normal and malignant cells (8–13). The
anti-EGFR mAb-mediated inhibition of cell proliferation has
been attributed, at least in part, to the EGFR dimerization (13).
Other cellular effects of blockade of the EGFR signaling by
anti-EGFR mAbs include inhibition of cell cycle progression
(14), induction of apoptosis (15),2 enhanced chemosensitization
(17, 18), and inhibition of the repair efficiency of the damaged
DNA (reviewed in Ref. 19). Anti-EGFR mAbs have been shown
to block the capacity of ligand to activate receptor tyrosine
kinase in intact cells (13), but the kinase activity can be de-
tected in EGFR precipitated from cell lysates with anti-recep-
tor mAbs (8, 12).
The DNA-dependent protein kinase (DNA-PK) is a serine/
threonine kinase that consists of a 350-kDa catalytic subunit
and a heterodimeric regulatory complex Ku70/80 and can in
vitro phosphorylate a number of transcription factors and DNA
binding proteins, including p53, the RNA polymerase II car-
boxyl-terminal domain, replication factor A, and the Ku (20–
23). The carboxyl-terminal 380 amino acids of DNA-PK exhib-
its sequence homology with the catalytic domains of members
of the phosphatidylinositol (PI) 3-kinase superfamily (23). The
activity of DNA-PK has been shown to be inhibited by auto-
phosphorylation (24). The DNA-PK is believed to play a major
role in repairing double strand DNA breaks and V(D)J recom-
bination, as mutations of DNA-PKcs cause both x-ray sensitiv-
ity and defective V(D)J recombination (17, 23). Since efficient
DNA repair may require growth factor signaling (19, 25), it is of
interest to explore any linkage between EGFR-mediated sig-
naling and DNA-PK pathway. We report the results of exper-
iments demonstrating specific early physical interaction be-
tween EGFR and DNA-PK or Ku70/80 in mammalian cells in
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response to anti-EGFR mAbs and not in response to EGFR
ligands.
MATERIALS AND METHODS
Cell Culture and Immunoblotting—DiFi human colorectal carcinoma
cells (15, 26, 27),2 HER14 murine fibroblasts expressing human EGFR
(13, 28), A431 human epidermoid carcinoma cells (9), and MDA-MB453
human breast carcinoma cells (29) were maintained in Dulbecco’s mod-
ified Eagle’s medium-F-12 (1:1; Life Technologies, Inc.) supplemented
with 10% fetal calf serum (Life Technologies, Inc.). HeLa human cervi-
cal carcinoma cells (30) and U266 leukemic cells (ATCC) were cultured
in minimal essential medium (Life Technologies, Inc.) and RPMI (Life
Technologies, Inc.), respectively, supplemented with 10% fetal calf se-
rum. Antibodies against DNA-PK (clones 24-5, 18-2 and 42-psc), Ku70/
80, and EGFR (clones 11E8 and H11) were purchased from the Neo-
marker Inc. (Fremont, CA).
For preparation of cell extracts, cells were were washed three times
with phosphate-buffered saline and lysed in buffer (50 mM Tris-HCl, pH
7.5, 120 mM NaCl, 0.4% Nonidet P-40, 100 mM NaF, 200 mM NaVO5, 1
mM PMSF, 10 mg/ml leupeptin, 10 mg/ml apotinin) for 15 min on ice. The
lysates were centrifuged in an Eppendorf centrifuge at 4 °C for 15 min.
Cell lysates containing equal amounts of protein were resolved on a 7%
SDS-PAGE, transferred to nitrocellulose, and probed with the appro-
priate antibodies by using an ECL method or alkaline phosphatase-
based color reaction method (30, 31).
Metabolic Labeling and Immunoprecipitation—An equal number of
cells were metabolically labeled for 6 or 3 h with 100 mCi/ml [35S]me-
thionine in methionine-free medium containing 2% fetal bovine serum
in the absence or presence of mAb 225. Alternately, cells were labeled
for 3 h and treated with mAb for the last 30 min of culture before
harvesting. Cells extracts were prepared as described above. Cell ex-
tracts containing an equal amount of total trichloroacetic acid-percep-
tible counts were immunoprecipitated with the desired mAb or control
rabbit anti-mouse-protein A conjugate, resolved on a SDS-polyacryl-
amide gel, and analyzed by autoradiography (29–32).
EGFR Intrinsic Kinase Assay—Cell lysates were immunoprecipi-
tated with EGFR or DNA-PK or Ku70/80 mAbs, and EGFR kinase
activity was measured by a immune complex kinase assay as described
(33). Reaction products were resolved by SDS-PAGE, transferred to a
nitrocellulose membrane, and visualized by autoradiography. When
indicated, subsequent to autoradiography, the blot was immunoblotted
with the appropriate mAbs to confirm the identity of phosphorylated
protein bands.
Subcellular Fractionation—Cytosolic and nuclear extracts were pre-
pared from unlabeled or metabolically labeled cells as described (32,
34). Briefly, cells were washed with phosphate-buffered saline and
pelleted at 1500 rpm for 5 min. Cells were resuspended in 200 ml of
ice-cold lysis buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA,
0.4% Nonidet P-40, 0.5 mM dithiothreitol, 0.5 mM PMSF, 1 mM sodium
vanadate, 1 mM sodium fluoride) and by gently pipetting up and down
10 times and left on ice for 5 min. The lysate was spun for 1 min to
separate nuclei, and supernatant was transferred to a new tube. For
cytosol preparation, the supernatant was centrifuged at 15,000 rpm for
15 min. Nuclei were washed with 500 ml of lysis buffer and resuspended
in 200 ml of nuclear extraction buffer (20 mM HEPES, pH 7.9, 0.4 M
NaCl, 1 mM EDTA, 1 mM dithiothreitol, 0.5 mM PMSF, 1 mM sodium
vanadate, 1 mM sodium fluoride), vigorously shaken at 4 °C for 15 min,
centrifuged at 15,000 rpm for 15 min, and the supernatant (nuclear
extracts) was transferred to a new tube.
DNA-PK Activity Assay—For assaying the DNA-PK kinase activity,
cytosolic and nuclear fractions (35) were prepared and assayed using a
peptide substrate (EPPLSQEAFADLWKK, purchased from the Pro-
mega) specific for DNA-PK as per the manufacture’s instructions (36,
37). As control, DNA-PK kinase reaction was performed with or without
enzyme or DNA or peptide substrate. Purified DNA-PK (Promega) was
used as a positive control.
Immunofluorescence Confocal Studies—Cellular localization of
DNA-PK was determined using indirect immunofluorescence as de-
scribed (38), with some modification. Briefly, cells grown on glass cov-
erslips were fixed (without permeabilization) in acetone at 220 °C for 3
min. Several dilutions of each antibody were used to obtain the optimal
results. For staining of DNA-PK, DiFi cells were treated with or without
anti-DNA-PK mAb 25–4 followed by TRITC-labeled goat anti-mouse
secondary antibody (Molecular Probes). For controls, cells were treated
only with the TRITC-goat anti-mouse antibody, omitting the primary
antibody, and no signals were detected in control untreated cells. Also,
there was no significant staining background by either FITC-goat an-
tibody or by rabbit EGFR antibody. Each image represents Z sections at
the same cellular level and magnification. Confocal analysis was per-
formed using a Zeiss laser scanning confocal microscope using the
established methods, involving processing of the same section for each
detector (the two excitations corresponding to FITC and TRITC) and
comparing pixel by pixel. Co-localization of two proteins is demon-
strated by the development of yellow color due to red and green pixels.
RESULTS AND DISCUSSION
During an investigation on the expression of DNA-PK in
DiFi human colorectal cells (15)2 treated with anti-EGFR mAb
225, we observed that immunoprecipitation (IP) of 35S-labeled
cell lysates with an antibody (clone 25-4) against the catalytic
subunit of DNA-PK (DNA-PK) co-immunoprecipitated a pro-
tein of approximate molecular mass of 170 kDa in mAb 225-
treated cells, but not in control cells (Fig. 1A). Based on the size
of 170 kDa, we explored the possibility that the observed DNA-
PK-associated protein could be EGFR. Supernatants from
DNA-PK IP were re-immunoprecipitated with anti-EGFR mAb
528 (9, 10). Results indicated that there was almost complete
absence of EGFR in lysates of mAb 225-treated cells that had
been subjected to IP with anti-DNA-PK mAb (Fig. 1B). The
lower panel in Fig. 1B shows the levels of total EGFR protein in
mAb 225-treated lysates of mAb 225-treated DiFi cells as de-
termined by direct immunoblotting with an anti-EGFR mAb
(clone 11E8, raised against a fusion protein containing 330
amino acids of the cytoplasmic domain of EGFR) (39). Since
activation of DNA-PK requires interaction with its regulatory
subunits Ku70 and Ku80, 35S-labeled cell lysates from control
and mAb 225-treated (3 h) DiFi cells were immunoprecipitated
with an anti-Ku70/80 mAb that recognizes the Ku70/80 het-
erodimer or with anti-EGFR mAb 528. Treatment of DiFi cells
with mAb 225 also resulted in increased association of a 170-
kDa protein band with Ku70/80 (Fig. 1C, lanes 5 and 6). As
expected from previous studies (9, 10), mAb 225 treatment
resulted in a modest reduction in newly synthesized EGFR
(Fig. 1C, lanes 3 and 4). However, re-IP of supernatants from
lanes 3 and 4 with anti-DNA-PK mAb 25-4 demonstrated a
significant increase in the levels of co-IP 170-kDa protein band
with DNA-PKcs only in mAb 225-treated cell lysates (Fig. 1C,
lanes 7 and 8). Co-immunoprecipitation of 35S-labeled 170-kDa
protein with DNA-PK was also observed with two other anti-
DNA-PK mAbs, clones 18-2 and 42-psc (data not shown). Re-
sults in Fig. 1D demonstrate the specific interaction between
DNA-PK and EGFR in DiFi cells treated with mAb 225 for 30
min. In brief, these observations indicated that treatment of
DiFi cells with anti-EGFR mAb 225 triggers early physical
interaction of a 170-kDa protein (presumably EGFR) with both
catalytic and regulatory subunits of DNA-PK.
To examine whether the observed interaction between 170-
kDa protein and DNA-PK could be also detected during EGFR
activation by its ligand, we compared the effect of TGF-a treat-
ment (30 min) on metabolically labeled DiFi cells with that of
anti-EGFR mAbs 225 and 528-treated (30 min) cells. As a
control, an unrelated antibody 4D5 against HER2 receptor (29)
was used. DiFi cells have easily detectable levels of HER2 (Fig.
2B). As expected, activation of EGFR by its ligand TGF-a, but
not anti-EGFR mAbs, resulted in a mobility shift of EGFR due
to increased phosphorylation (Fig. 2A, upper panel, lanes 2 and
3). In contrast, in spite of EGFR activation by TGF-a (or EGF,
data not shown), there was no co-IP of a 170-kDa protein band
with DNA-PK. Treatment of DiFi cells with both anti-EGFR
mAbs 225 and 528, and not 4D5, resulted in a rapid association
of 170-kDa protein with DNA-PKcs (Fig. 2A, middle panel,
lanes 4 and 5). Association of the 170-kDa EGFR protein band
with anti-DNA-PK immunoprecipitates from mAb 225-treated
DiFi cells was readily detectable by staining with Coomassie
Brilliant Blue (Fig. 2A, lower panel). To further establish the
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identity of 170-kDa protein as EGFR, we next immunprecipi-
tated cell lysates from DiFi cells treated with TGF-a or mAb
225 for 30 min and immunoblotted with anti-DNA-PK mAb or
anti-EGFR mAb 11E8 or Ku70/80 mAb. Results in Fig. 2C
confirmed that mAb 225 induces the association between
EGFR and DNA-PK (lane 3) or Ku70/80 (lane 6). The associa-
tion of EGFR with DNA-PK was also established by stripping
the above blots and re-immunoblotting with an another anti-
EGFR polyclonal antibody RK2 (Ref. 40, raised against a pep-
tide corresponding to amino acids 985–996 of EGFR) or with a
different anti-EGFR-mAb H11 (Ref. 41, raised against extra-
cellular domain of EGFR) (data not shown).
mAb-induced interaction between EGFR and DNA-PK or
Ku70/80 in mAb 225-treated cells was specific to mAb 225,
which also induced physical interaction between EGFR and
DNA-PK or Ku70/80 in murine fibroblast NIH 3T3 cells engi-
neered to express human EGFR (HER14 cells; Ref. 16) (Fig. 3A,
lanes 2 and 5). Data in Fig. 3B demonstrate that the observed
interaction between EGFR and DNA-PK in mAb 225-treated
HER14 cells could be also detected by immunoprecipitation of
cell lysates with anti-EGFR mAb.
To determine whether DNA-PK-associated EGFR was func-
tionally active, we next performed a EGFR in vitro intrinsic
kinase assay using anti-DNA-PK and anti-Ku immunoprecipi-
tates. As a positive control, anti-EGFR immunoprecipitates
from control and TGF-a-stimulated A431 cell lysates were used
(Fig. 4A, lanes 1 and 2). The EGFR tyrosine kinase displayed
the capacity to autophosphorylate EGFR in both anti-DNA-PK
and anti-Ku immunoprecipitates from mAb 225-treated DiFi
cells (Fig. 4A). There was no effect of TGF-a or mAb 225
FIG. 1. Anti-EGFR mAb 225 induces association of a 170-kDa
protein with DNA-PK or Ku70/80. A, DiFi cells were metabolically
labeled with 100 mCi/ml [35S]methionine for 3 h (lanes 1 and 2) or 6 h
(lanes 3 and 4) in the presence or absence of 30 nM mAb 225. Total cells
extracts containing an equal amount of total trichloroacetic acid-pre-
cipitable counts (or equal amount of protein in case of unlabeled cell
lysates) were immunoprecipitated with anti-DNA-PK mAb 25-4 and
analyzed by SDS-PAGE and autoradiography. B, supernatants from the
above DNA-PK IP were re-immunoprecipitated with anti-EGFR mAb
528 and analyzed as above. Lower panel, cell lysates were immuno-
blotted with anti-EGFR mAb 11E8 using alkaline phosphatase color
method. C, DiFi cells were labeled with [35S]methionine for 3 h in the
presence or absence of 30 nM mAb 225. Total cell lysates were immu-
noprecipitated with anti-DNA-PK mAb 25-4 (lanes 1 and 2) or anti-
EGFR mAb 528 (lanes 3 and 4) or anti-Ku70/80 mAb (lanes 5 and 6).
Supernatants from lanes 3 and 4 were re-immunoprecipitated with
anti-DNA-PK mAb 25-4 (lanes 7 and 8) and analyzed by SDS-PAGE and
autoradiography. l, DNA-PK; *, Ku70/80. D, DiFi cells were labeled
with [35S]methionine for 3 h and treated with or without 30 nM mAb 225
during the last 30 min before harvesting. Cell lysates containing equal
amount of trichloroacetic acid-perceptible counts were immunoprecipi-
tated with anti-DNA-PK mAb 25-4 (lanes 3 and 4) or control rabbit
anti-mouse (RAM)-protein A conjugate (lanes 1 and 2). Samples were
resolved on a 7% SDS-PAGE and analyzed by autoradiography. Quan-
titation of radioactivity associated with the EGFR band is shown in the
lower panel.
FIG. 2. Anti-EGFR mAbs, and not EGFR ligands, trigger inter-
action between EGFR and DNA-PK or Ku70/80. A, DiFi cells were
metabolically labeled with [35S]methionine for 3 h and treated with or
without 30 nM TGF-a (lanes 2 and 3) or 30 nM mAb 225 (lane 4) or 30 nM
mAb 528 (lane 5) or 30 nM mAb 4D5 (lane 6) for 30 min before cells
harvesting. Cell lysates were immunoprecipitated with anti-EGFR
mAb 528 and analyzed as SDS-PAGE and autoradiography (upper
panel). Cell lysates from the above samples were immunoprecipitated
with anti-DNA mAb 25-4 and analyzed by autoradiography (middle
panel) or Commassie Brilliant Blue (lower panel). B, 35S-labeled DiFi
cells were treated with or without 30 nM mAb 4D5 for 30 min. Cell
lysates were immunoprecipitated with another anti-HER2 mAb clone
N12 (Neomarker). C, DiFi cells were treated for 30 min with or without
30 nM TGF-a (lanes 2 and 5) or 30 nM mAb 225 (lanes 3 and 6). Cell
lysates were immunoprecipitated with anti-DNA-PK mAb 25-4 (lanes
1–3) or anti-Ku70/80 mAb (lanes 4–6) and blotted with anti-DNA-PK
mAb (upper panel) or anti-EGFR mAb 11E8 (middle panel) or Ku70/80
mAb (lower panel) from the same blot.
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treatment upon the status of DNA-PK phosphorylation in these
assays (Fig. 4A, lanes 3–5). Subsequent to autoradiography, the
identity of the phosphorylated protein bands was confirmed by
immunoblotting with specific mAbs against DNA-PK or EGFR
(Fig. 4B). There was no effect of mAb 225 treatment on the
activity of DNA-PK in cell lysates, using GAL4-CTD (34, 35) as
a substrate (data not shown). Taken together, these results
demonstrated that treatment of DiFi cells with anti-EGFR
mAb 225, but not with EGFR ligands, leads to interaction of
EGFR with DNA-PKcs or Ku70/80.
To further study the interaction between EGFR and DNA-
PK, we next performed mixing experiments involving isolation
of DNA-PK or Ku70/80 from U266 human leukemic cells that
lack EGFR and then incubation with cell lysates from HER14
cells. DNA-PK and Ku70/80 immunoprecipitates from U266
cells were incubated for 2 h with cell lysates from control or
mAb 225-treated HER14 cells, and the beads were washed and
immunoblotted with anti-EGFR mAb 11E8 or control antibod-
ies. Results in Fig. 4C demonstrate that EGFR from mAb
225-treated HER14 cells, and not from untreated HER14 cells,
interacted with DNA-PK and Ku70/80. DNA-PK has been
shown to have significant homology with PI 3-kinase, which is
a downstream target of EGFR signaling. Most, if not all, known
functions of EGFR require EGFR kinase activity. We examined
the involvement of PI 3-kinase and EGFR kinase in mediating
the interaction between DNA-PK and EGFR. The PI 3-kinase
inhibitor wortmannin and the EGFR kinase inhibitor tyrphos-
tin A9 did not prevent the interaction between EGFR and
DNA-PK in DiFi cells (Fig. 4D). As expected, tyrphostin A9
reduced the phosphorylation of EGFR, as demonstrated by the
band shift in lanes 5 and 6.
DNA-PK has been shown to be primarily localized in the
nucleus (21–23). Our finding of physical interaction between
EGFR and DNA-PK has raised the possibility of redistribution
of DNA-PK in response to anti-EGFR mAbs. To examine the
effect of mAb 225 on the subcellular localization of DNA-PK,
DiFi cells were treated with mAb 225 for 30 min, and cytosolic
and nuclear extracts were prepared. As expected, a major frac-
tion of DNA-PK was localized in the nucleus and a minor
fraction in the cytosol (Fig. 5A, upper panel), and EGFR was
present in the cytosol (Fig. 5A, middle panel). Treatment with
mAb 225 was accompanied by a reduction in the level of nu-
clear DNA-PK. Ku80 was localized in the cytosolic and nuclear
extracts. Subcellular fractionation of 35S-labeled DiFi cells
treated with mAb 225 indicated that EGFR interacts with the
cytosolic fraction of DNA-PK (Fig. 5B, lane 2) and also con-
firmed a decrease in the amount of the nuclear DNA-PK (Fig.
5B, compare lane 4 with lane 3). To determine whether the
observed reduction in the amount of the nuclear DNA-PK is
functional, we measured the DNA-PK kinase activity in the
cytosolic and nuclear fractions from control and mAb 225-
treated DiFi cells using a peptide substrate specific for
DNA-PK (36, 37). Results in Fig. 5C demonstrate that DNA-PK
activity was primarily localized in the nuclear fraction in con-
FIG. 3. A, HER14 cells were treated with or without 30 nM mAb 225
or control IgG for 30 min. Cell lysates were immunoprecipitated with
DNA-PK (lanes 1–3) or Ku70/80 (lanes 4–6) or control mouse IgG (lane
7) and blotted with DNA-PK (upper panel) or EGFR (lower panel) mAbs
from the same blot. B, HER14 cells were treated with or without 30 nM
mAb 225 for 30 min, and cell lysates were immunoprecipitated with
anti-EGFR mAb 528 and blotted with DNA-PK mAb (upper panel) or
anti-EGFR mAb 11E8 (lower panel) from the same blot.
FIG. 4. Autophosphorylation of EGFR associated with DNA-
PK. A, DiFi cells were treated DiFi cells were treated for 30 min
without or with 30 nM TGF-a (lanes 5 and 8) or 30 nM mAb 225 (lanes
4 and 7). Two sets of cell lysates were immunoprecipitated with anti-
DNA-PK mAb (lanes 3–5) or anti-Ku70/80 mAb (lanes 6–8). As EGFR
kinase control, A431 cells were treated with 30 nM TGF-a for 15 min
and immunoprecipitated with anti-EGFR mAb 528 (lanes 1 and 2).
After immunoprecipitated, one set of precipitated EGFR was subjected
to in vitro kinase assay, analyzed by SDS-PAGE, transferred to nitro-
cellulose, and autoradiograph resulted from 1-h exposure is shown here
(upper panel). The second set of precipitated EGFR was analyzed by
SDS-PAGE, transferred to nitrocellulose, and immunoblotted with anti-
phosphate-Tyr. mAb PY-20 (lower panel). B, to confirm the identity of
phosphorylated protein bands in A (upper panel), subsequent to auto-
radiography, the membrane was blotted with DNA-PK or EGFR mAbs,
using a color reaction method of detection (as in Fig. 1B, lower panel).
C, DNA-PK associates with EGFR in vitro. DNA-PK and Ku70/80 were
purified from U266 cells by IP, and the beads were further incubated for
2 h with cell lysates from control and mAb 225-treated (30 nM) HER14
cells. Beads were analyzed by SDS-PAGE and immunoblotted with
DNA-PK (upper panel) or EGFR (middle panel) or Ku80 (lower panel)
mAbs from the same blot. D, DiFi cells were labeled with [35S]methi-
onine for 3 h and treated with or without 30 nM mAb 225 in the presence
or absence of wortmannin (Wort) (Sigma) or tyrphostin A9 (Tyroph)
(Calbiochem) for 30 min before preparing cell lysates. Cell lysates were
immunoprecipitated with anti-DNA-PK mAb 25–4 and analyzed by
SDS-PAGE and autoradiography.
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trol cells, and treatment with mAb 225 was accompanied with
75% reduction in the levels of the nuclear DNA-PK activity.
Data in Fig. 5D illustrate the effect of mAb 225 on the activity
of DNA-PK in the cytosolic fraction as a function of enzyme
concentration.
The observed interaction between EGFR and DNA-PK in
mAb 225-treated cells was further validated by confocal micros-
copy (Fig. 6). mAb 225 treatment of DiFi cells was accompanied
by a significant reduction in the amount of DNA-PK (shown by
arrowheads) in the nucleus (shown by arrows that are located
just under the nuclear membrane) (panel C). As a control, mAb
225-treated DiFi cells were stained without DNA-PK mAb (Fig.
6D, red staining). Results in Fig. 6E demonstrate the develop-
ment of yellow color due to co-localization of red (DNA-PK) and
green (internalized EGFR) pixels in mAb 225-treated cells
(shown by arrowhead). In brief, these results revealed that a
substantial amount of DNA-PK was co-localized with the in-
ternalized EGFR in anti-EGFR mAb-treated cells.
To examine the generality of physical interaction between
EGFR and DNA-PK, we extended our investigation to A431
human epidermoid carcinoma cells (which express high level of
EGFR), HeLa human cervical carcinoma cells (which express
normal level of EGFR), and MDA453 human breast carcinoma
cells (which lack EGFR). mAb 225 treatment also stimulated
the interaction between EGFR and DNA-PK in A431 cells and
HeLa cells (Fig. 7, lanes 4 and 6), but not in EGFR minus
MDA453 cells (lanes 7 and 8). Data in Fig. 7 also demonstrate
that there was some base-line interaction between EGFR and
DNA-PK in A431 cells (lanes 1 and 3), which was specifically
increased by mAb 225 (lane 4), but not by TGF-a (lane 2). In
brief, our results suggested that the observed interaction be-
tween EGFR and DNA-PK in mAb 225-treated cells was de-
pendent on the presence of EGFR, but not the levels of EGFR.
mAbs against the extracellular domain of EGFR have been
widely considered as potential antiproliferatve therapeutic
agents. Our findings demonstrate that incubating cells with
anti-EGFR mAbs, and not with EGFR ligands, triggers a spe-
cific physical interaction between EGFR and DNA-PKcs and
EGFR and Ku70/80 in a variety of cell types. This can be
demonstrated both in vivo and in vitro. The anti-EGFR mAb-
induced interaction between EGFR and DNA-PK or Ku70/80
was dependent on the presence of EGFR, but not on the amount
FIG. 5. Effect of mAb 225 on subcellular distribution of DNA-
PK. A, cytosolic and nuclear extracts from control and mAb 225-treated
DiFi cells were immunoblotted with DNA-PK (upper panel) or EGFR
(middle panel) or Ku80 (lower panel) mAbs. B, DiFi cells were labeled
with [35S]methionine for 3 h and treated with (lanes 2 and 4) or without
(lanes 1 and 3) 30 nM mAb 225 for 30 min. Cytosolic and nuclear
extracts were immunoprecipitated with anti-DNA-PK mAb 25-4 and
analyzed by SDS-PAGE and autoradiography. C, 10mg of cytosolic (open
bars) or nuclear (solid bars) extracts from control or mAb 225-treated
DiFi cells were assayed for DNA-PK activity as described (34). Results
are expressed as the percentage of total activity (100%) in each fraction.
D, increasing amount of cytosolic extracts from control (open bars) or
mAb 225-treated (solid bars) DiFi cells were assayed for DNA-PK
activity. Results are expressed as the total count per minute (CPM)
incorporated in the peptide substrate.
FIG. 6. Immunofluorescence co-localization of EGFR and
DNA-PK in DiFi cells. Cells were grown on coverslip and treated with
mAb 225 (C, D, and E) or without mAb (A and B) for 30 min and fixed.
After blocking, cells were double-stained using affinity-purified mouse
anti-DNA-PK mAb (A, C, and E, upper and bottom panels), and rabbit
anti-EGFR Ab (B and E, middle and bottom panels). Control pattern of
staining due to mAb 225 is shown in D. Primary antibodies (DNA-PK
and mAb 225) were detected using rhodamine (TRITC)-conjugated
goat-anti-mouse IgG or fluorescein-conjugated goat-anti-rabbit IgG for
the detection of EGFR. Large arrowheads in A and C show nuclear or
extranuclear localization of DNA-PK (red staining). Yellow color in E
(bottom frame) represents co-localization of red and green colors; ex-
tranuclear co-localization of internalized EGFR and DNA-PK is shown
by the arrowhead; yellow color on the outer membrane represents
co-localization of surface membrane-associated EGFR and mAb 225.
FIG. 7. Interaction between EGFR and DNA-PK or Ku70/80 in
diverse cell types. A431 cells, HeLa cells, and MDA-MB-453 cells
were treated without or with 30 nM mAb 225 (lanes 4, 6, and 8) or TGF-a
(lane 2) for 30 min. Cell lysates were immunoprecipitated with DNA-PK
and blotted with DNA-PK (upper panel) or EGFR (lower panel) mAbs.
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of receptor. The tyrosine kinase in DNA-PK-associated EGFR
remains active in the anti-EGFR mAb-treated cells. The poten-
tial significance of the observed interactions between EGFR
and DNA-PK and Ku70/80 in the response to anti-EGFR mAbs
remains to be delineated. Some of the known functions of
DNA-PK include repairing double strand breaks and V(D)J
recombination and phosphorylation of a number of transcrip-
tion factors (21–23). In this context, our finding that mAb 225
induces a reduction in the level of DNA-PK in the nucleus is
important, as it implies a possible role of EGFR-signaling in
maintenance of the nuclear levels of DNA-PK, and interference
in EGFR signaling may possibly result in the impairment of
DNA repair activity in the nuclei of anti-EGFR mAb-treated
cells.
Our findings raise new questions about the intracellular
events that results from blockade of EGFR tyrosine kinase by
anti-EGFR mAbs. Inhibition of signal transduction pathways
activated by the EGFR tyrosine kinase may alter the status of
proteins that mediate interaction between EGFR and DNA-PK,
and the reduced phosphorylation status of the receptor may
facilitate the interaction. Alternatively, receptor dimerization
(without kinase activation) induced by mAb 225 may activate a
signal that leads to the observed interaction, since kinase in-
activation by tyrphostin A9 in the absence of mAb 225 did not
result in EGFR-DNA-PK interaction. The roles of the EGFR
and the DNA-PK associated with each other, and the structure-
function relationship between EGFR and DNA-PK requires
further experimentation. In summary, our findings demon-
strate the possible existence of a novel cellular pathway that
involves physical interaction between EGFR and DNA-PK or
Ku70/80 in response to blockade of EGFR signaling by specific
mAbs.
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